Navigation Links
Pharmasset to Present at the UBS Global Life Sciences Conference
Date:9/17/2010

tly have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys(R) plus Copegus(R) and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently initiated 12 weeks of dosing in a Phase 2b study, and PSI-938, an unpartnered guanosine nucleotide analog in a Phase 1 study. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development. Racivir, for the treatment of HIV, has completed a Phase 2 clinical study.

Pegasys(R) and Copegus(R) are registered trademarks of Roche. ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice:

+1 (609) 613-4181Forward-Looking Statements Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important fac
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
2. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
3. Pharmasset Reports Fiscal Year End 2009 Financial Results
4. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
5. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
6. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
7. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
8. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
9. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
10. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
11. Pharmasset Reports Fiscal Year End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015  Abaxis, Inc. (NasdaqGS: ABAX ), a ... today that Ross Taylor , vice president of ... of chief financial officer effective August 1, 2015, will ... Thursday, June 4, 2015 at 10:00 a.m. ET. The ... New York City . ...
(Date:5/27/2015)... DUBLIN, Ohio , May 27, 2015 /PRNewswire/ ... present a new series of health economic outcomes ... evaluating real-world treatment patterns when developing value-based reimbursement ... , vice president and chief medical officer of ... and pharmaceutical companies alike have known for more ...
(Date:5/27/2015)... , May 27, 2015  Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced today that it ... on Monday, June 1, 2015 at the Luxe Sunset ... The presentation by Michael Becker ... development, is scheduled to begin at 2:00 p.m. PT/5:00 ...
Breaking Medicine Technology:New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 2New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 3Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference 2Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference 3
... Feb. 27, 2012  Ventana Medical Systems, Inc. (Ventana), a member ... U.S. Food and Drug Administration (FDA) for the VENTANA ... the VENTANA iScan Coreo Au scanner running ... company offering an FDA cleared Ki-67 image analysis algorithm ...
... Feb. 27, 2012 Accuray Incorporated (Nasdaq: ARAY ... president and chief executive officer, Euan S. Thomson, Ph.D., is ... in Boston on Tuesday, March 6, 2012 at 8:00 a.m. ... presentations will be available online from the Investor Relations page ...
Cached Medicine Technology:Ventana Receives FDA Clearance for Ki-67 (30-9) Image Analysis and Digital Read Applications 2Accuray Incorporated's CEO to Speak at Cowen and Company 32nd Annual Healthcare Conference 2
(Date:5/27/2015)... Jose, CA (PRWEB) May 27, 2015 Splashtop ... its latest addition to its screen mirroring and extended display ... Whether in a conference room, classroom, or family room, users ... a large TV / display connecting to an Apple TV, ... Amazon Fire TV, Amazon Fire TV Stick, or the Google ...
(Date:5/27/2015)... CRN International, the radio marketing and promotions ... Financial Officer. , Prinner most recently was Principal of ... financial/operational executive positions at telecom and technology services companies ... and SNET. His accounting and consulting career began ... will be able to tap into his experience of ...
(Date:5/27/2015)... Louisville, KY (PRWEB) May 27, 2015 ... or worse because of lack of compliance documentation or ... a recycler in Miami, a propane gas company in ... doling out fines for incidents and accidents due to ... System (LMS) is proud to introduce the new ...
(Date:5/27/2015)... TX (PRWEB) May 27, 2015 Congratulations ... The Torch” Addiction Treatment Scholarship Award. From June 1, ... $10,000 to 50 drug and alcohol addiction treatment centers ... treatment. Scholarships were drawn at random at addiction treatment ... for Sky Toxicology, Matt Green said, “Sky Toxicology would ...
(Date:5/27/2015)... 2015 Altec Products, Inc., a leader ... their Premier Sponsorship of Connections 2015. The all-day client ... Thursday, May 28th and will deliver to clients both ... the roadmap to get there. , Arxis Technology, ... sale, installation and support of Intacct Cloud Financials, Adaptive ...
Breaking Medicine News(10 mins):Health News:Splashtop Launches the Fastest Computer Screen Mirroring and Extended Display Solution – to Apple TV and other Smart Displays 2Health News:Splashtop Launches the Fastest Computer Screen Mirroring and Extended Display Solution – to Apple TV and other Smart Displays 3Health News:CRN International Names New Chief Financial Officer 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 3Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 2Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 3Health News:Altec Sponsors Connections 2015, Arxis Technology, Inc.’s Client Conference, Bringing Valuable Document Management Solution to Attendees 2Health News:Altec Sponsors Connections 2015, Arxis Technology, Inc.’s Client Conference, Bringing Valuable Document Management Solution to Attendees 3
... OUT TO EDUCATE CHICAGOANS, CHICAGO, Jan. 25 ... of Chicago, SAVE THE PATIENT, a,not-for-profit patient-focused organization, is ... Access Network (CAN-TV) and,will air on Monday, January 28, ... will feature a frank discussion on how to make ...
... study finds , , FRIDAY, Jan. 25 (HealthDay News) ... States hit $174 billion in 2007, a 32 percent ... research, commissioned by the American Diabetes Association (ADA), found ... $116 billion, and a disproportionate percentage of those costs ...
... Time with,Friends and Family, SACRAMENTO, Calif., Jan. 25 ... senior citizen center to enjoy the company,of other seniors. ... for her to go to the dining room, and ... donated by The SCOOTER Store,Mrs. Pittman can now enjoy ...
... needed to confirm the findings, experts say , , FRIDAY, Jan. ... lutein could lower a woman,s risk of sight-robbing cataracts, new ... 35,000 women aged 45 and older. , "The data suggests ... total vitamin E may have a lower risks of cataracts," ...
... Inc. (NYSE:,WLP) announced today that senior management is ... January 30, 2008. The presentation is,expected to begin ... interested parties are invited to listen to the ... and selecting the "Investor,Info" link. Following the presentation, ...
... WARSAW, Ind., Jan. 25 Symmetry Medical Inc.,(NYSE: ... to the global orthopaedic,device industry and other medical ... announced acquisition of DePuy Orthopaedics, Inc,s,facility for orthopaedic ... in cash., As originally announced in December ...
Cached Medicine News:Health News:Making the Most Out of Your Doctor's Visit 2Health News:Diabetes' Health Toll Hits $174 Billion Annually 2Health News:Disabled Sacramento Woman, 110, Receives Power Wheelchair Donation from The SCOOTER Store 2Health News:Vitamin E, Lutein May Fight Cataracts 2Health News:Vitamin E, Lutein May Fight Cataracts 3Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Symmetry Medical Completes Acquisition of DePuy Orthopaedic Instrument Facility 2
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used to gain percutaneous access into the renal pelvis to treat stone disease. The dual lumen catheter and the Peel-Away® introducer are sized for use in pediatric patients. Supplied sterile in p...
Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The wire guide has an extra stiff shaft and a gradual transition to a very flexible tip. Supplied sterile in peel-open packages. ...
Medicine Products: